|
FEBRUARY 4, 2008 |
|
8:00 – 8:45 am |
Registration & Continental Breakfast
|
|
8:45 – 9:00 |
Welcome & Opening Remarks
Howard Fillit, MD, Executive Director, ADDF
|
|
9:00 – 9:30 |
Plenary Talk:
An Overview of Drug Discovery for Neurodegenerative Disease
Jeffrey S. Nye, MD, PhD, Vice President,
Experimental Medicine, Johnson and Johnson
Pharmaceutical R&D, LLC (confirmed) |
|
I. Target Identification & Validation: How
Our Understanding of the Biology of
Neurodegeneration Can Be Employed
Chair: Peter Reinhart, PhD, Wyeth
Research
(confirmed) |
|
9:30 – 9:35 |
Session Overview - Peter Reinhart, PhD |
|
9:35 – 10:00 |
Mechanisms of Neurodegeneration that are Drugable:
A Pharmaceutical Perspective
Peter Reinhart, PhD, Wyeth Research
(confirmed) |
|
10:00 – 10:25 |
Novel Targets for CNS Drug Discovery: an
Academic Perspective
Linda Van Eldik, PhD, Northwestern
University
(confirmed) |
|
10:25 – 10:40 |
BREAK |
|
10:40 – 11:05 |
Target Validation in CNS
Drug Discovery
Barbara Sahagan, PhD, Pfizer, Inc.
(confirmed) |
|
11:05 – 11:35 |
Q & A |
|
II.
Lead Identification & Optimization: Unique
Aspects of Chemistry in Neurodegenerative Disease
Chair: D. Martin Watterson, PhD,
Northwestern University
(confirmed) |
|
11:35 – 11:40 |
Session Overview -
D. Martin Watterson, PhD |
|
11:40 – 12:05 |
Hits to Leads to Drugs: What Makes a
Chemical a Drug
Christopher A. Lipinski, PhD, Melior
Discovery (confirmed) |
|
12:05 – 12:30 pm |
Rational Design and Medicinal Chemistry
Refinement in CNS Drug Discovery: Principles
and Case Studies
Richard Silverman, PhD,
Northwestern University (confirmed) |
|
12:30 – 1:30 |
LUNCH |
|
1:30 – 1:55 |
From Inhibitor to CNS Drug: Case Study of
Secretase Inhibitors
Jordan Tang, PhD, Oklahoma Medical Research
Foundation (confirmed) |
|
1:55 – 2:20 |
Biologics as Therapeutics: Special Issues
Peter Seubert, PhD, Elan Pharmaceuticals
(confirmed) |
|
2:20 – 2:50 |
Q & A |
|
III. Lead Discovery: In-Vitro Models of
Neurodegenerative Disease
Chair: Ross Stein, PhD,
Harvard Medical School & Brigham and Women’s
Hospital
(confirmed) |
|
2:50 – 2:55 |
Session Overview -
Ross Stein, PhD |
|
2:55 – 3:20 |
Developing Relevant High-Throughput
Assays for the Identification of Potential
Drug Candidates
Christopher Moxham, PhD, Merck Research
Laboratories (confirmed) |
|
3:20 – 3:35 |
BREAK |
|
3:35 – 4:00 |
Identification of Hits and Leads for
Neurodegenerative Diseases
Marcie Glicksman, PhD, Harvard Medical
School (confirmed) |
|
4:00 – 4:25 |
High-Throughput
Screening in Academia: Program Development &
Technology
Jill Heemskerk, PhD,
National
Institute of Neurological Disorders and
Stroke (confirmed) |
|
4:25 – 4:55 |
Q & A |
|
4:55 – 5:00 |
Closing Remarks
Howard Fillit, MD, Executive Director, ADDF |
|
5:00 – 7:00 |
NETWORKING RECEPTION |
|
FEBRUARY 5, 2008 |
|
8:00
– 8:30 am |
Continental Breakfast |
|
8:30 – 8:40 |
Welcome & Opening Remarks
Suzana Petanceska, PhD, National Institute on Aging
(confirmed)
|
|
IV. Pre-Clinical Proof-of-Concept &
Development: Neurodegenerative Disease
Chair: Jordan Tang, PhD, Oklahoma Medical
Research Foundation
(confirmed) |
|
8:40 – 8:45 |
Session Overview -
Jordan Tang, PhD |
|
8:45 – 9:10 |
Characteristics of Compounds that Cross the
Blood Brain Barrier
Douglas
Spracklin, PhD, Pfizer Global Research and
Development (confirmed) |
|
9:10 – 9:35 |
Requirements for a Lead Compound to Become a Clinical
Candidate
Franz
Hefti, PhD,
Avid Radiopharmaceuticals (confirmed)
|
|
9:35 – 10:00 |
What is Pre-Clinical Proof-of-Concept in Neurodegenerative Disease
Wayne Rowe, PhD, Memory Pharmaceuticals
(confirmed) |
|
10:00 – 10:15 |
BREAK |
|
10:15 – 10:40
|
The Basics of Pre-clinical Development
Edward Spack, PhD, SRI International
(confirmed) |
|
10:40 – 11:10 |
Q & A |
|
V. Resources and Services For Advancing Drug
Discovery
Chair: Neil Buckholtz, PhD, National
Institute on Aging
(confirmed) |
|
11:10 am – 11:15 pm |
Session Overview -
Neil Buckholtz, PhD |
|
11:15 – 11:40 |
Services for Early Drug Discovery
Duncan Beniston,
Chembridge Corporation (confirmed) |
|
11:40 am – 12:05 pm |
Resources at the National Institute of
Health
Neil Buckholtz, PhD, National Institute
on Aging (confirmed) and
Lorenzo Refolo,
PhD,
National Institute of Neurological Disorders
and Stroke
(confirmed) |
|
12:05 – 1:00 |
LUNCH |
|
1:00 – 1:25 |
Academic Models of Drug Discovery Services
Elias Michaelis, MD, PhD, University of Kansas
(confirmed) |
|
1:25 – 1:50 |
The FDA and Neurodegenerative Disease
Robert Powell, Food and Drug Administration (FDA)
(confirmed) |
|
1:50 – 2:20 |
Q & A |
|
2:20 – 2:35 |
BREAK |
|
VI. Disease specific issues in Drug
Discovery for Neurodegenerative Disease
Chair: Elias Michaelis, MD, PhD, University
of Kansas
(confirmed) |
|
2:35 – 2:40 |
Session Overview -
Elias Michaelis, MD, PhD |
|
2:40 – 3:40 |
Alzheimer’s disease
Facilitators – Frank Longo, MD,
PhD, Stanford University (confirmed)
Barry Greenberg, PhD, Neurochem,
Inc. (confirmed) |
|
|
Parkinson’s disease
Facilitators – Todd Sherer, PhD, Michael J.
Fox Foundation (confirmed)
Kalpana Merchant, PhD, Eli Lilly
and Company (confirmed) |
|
|
Huntington’s disease
Facilitators – Pierre Goloubinoff, PhD,
University of Lausanne (confirmed) and
Robert
Elfont, MD, PhD (confirmed) |
|
|
Amyotrophic Lateral Sclerosis
Facilitators –
Jeffrey Rothstein, MD, PhD, Johns Hopkins
University (confirmed)
and
Kenneth J. Rhodes,
PhD, Biogen Idec, Inc. (confirmed) |
|
|
'Orphan’ Neurological Diseases
Facilitators – Kim Hunter-Schaedle, PhD, Children’s
Tumor Foundation (confirmed)
Kate Haviland, PTC Therapeutics
(confirmed) |
|
3:40 – 4:35 |
Group Presentations |
|
4:35 – 4:45 |
Closing Remarks
Howard Fillit, MD, Executive Director, ADDF
|
PROGRAM